Evidence map›Paper›PMID 41748936›Full record

ArticleNPJ precision oncology2026

FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.

Santhosh Kumar Pasupuleti, Sravanti Rangaraju, Justin Layer, Kanaka Sai Ram Padam, Larry D Cripe, Hamid Sayar, Katie J Sargent, Jill Weisenbach, Heiko Konig, Huda Salman and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Santhosh Kumar Pasupuleti *Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Sravanti Rangaraju *Indiana University and Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Justin Layer *Indiana University and Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Kanaka Sai Ram PadamHerman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Larry D CripeIndiana University and Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Hamid SayarIndiana University and Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Katie J SargentIU Health Partners, Indianapolis, IN, USA.
Jill WeisenbachIndiana University and Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Heiko KonigIndiana University and Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Huda SalmanIndiana Cancer Research Center, Brown Center for Immunotherapy, Indianapolis, IN, USA.
Baskar RamdasHerman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Lakshmi Reddy PalamHerman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Lindsey D MayoHerman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Irum KhanNorthwestern University School of Medicine, Chicago, IL, USA.
Utpal P DavéIndiana University and Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
H Scott BoswellIndiana University and Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Reuben KapurHerman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA. rkapur@iu.edu.

Funding

Hypoxia CoreU54DK106846 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$857k
Role of p21 activated kinase in LeukemogenesisR01CA173852 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$369k
NIDDK NIH HHS U54 DK106846NIH HHS R01CA173852
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is sustained by oncogenic signaling and stress-adaptive networks that enable proliferative sustenance and therapeutic resistance. Transcriptomic profiling of AML blasts revealed upregulation of FLT3, SYK, HOXA9/10, and CTNNB1 with elevated oxidative phosphorylation (OXPHOS). Proteasome inhibition induced phosphorylation-dependent ubiquitination and nuclear export of β-catenin, triggering stress signaling (p62/SQSTM1/c-JUN/NRF2) and apoptosis in FLT3

Identifiers

PMID41748936
PMCPMC13111701

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.